Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

AI-guided antibody designer BigHat taps J&J as latest partner as internal pipeline advances

Still years away from the clinic, the biotech now has four deals with larger pharmas that are informing decisions around its wholly-owned programs

By Paul Bonanos, Director of Biopharma Intelligence
April 24, 2024 12:03 PM UTC

A deal with J&J to create optimized antibodies for neurological disorders is the latest step in BigHat’s evolution as it moves its internal pipeline of AI-designed biologics toward the clinic.

The agreement with the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) is the fourth with a large pharma for BigHat Biosciences Inc., after deals with AbbVie Inc. (NYSE:ABBV), Amgen Inc. (NASDAQ:AMGN) and Merck & Co. Inc. (NYSE:MRK). Financial terms and targets are undisclosed...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bighat Biosciences Inc.

Johnson & Johnson